HRTX Q1 2024 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$35M+17.1% YoY

Gross Profit

$26M75.6% margin

Operating Income

-$5M-13.8% margin

Net Income

-$3M-9.1% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+1.3%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$218M

Total Liabilities

$252M

Stockholders' Equity

-$34M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$30M	+17.1%
Gross Profit	$26M	$13M	+105.5%
Operating Income	-$5M	-$33M	+85.5%
Net Income	-$3M	-$33M	+90.4%

Revenue Segments

C I N V A N T I

$26M75%

Z Y N R E L E F

$5M15%

S U S T O L

$4M11%